12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

CB-315 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation for CB-315 to treat Clostridium difficile-associated diarrhea (CDAD) and CXA-201 to treat complicated intra-abdominal infection. CB-315 is an oral antibacterial lipopeptide in Phase III testing to treat...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >